We recently compiled a list of the 10 Firms Post Impressive Gains on Monday. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other stocks. Wall Street ended the first trading day of the week on a mixed note,

Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the fourth quarter but as lower sales guidance for the year stoked fears of tougher times ahead.

Analysts on Wall Street project that Johnson & Johnson (JNJ) will announce quarterly earnings of $2 per share in its forthcoming report, representing a decline of 12.7% year over year. Revenues ...

Johnson & Johnson beat Wall Street’s fourth-quarter expectations as strong cancer drug sales compensated for a decline in demand for the company’s blockbuster psoriasis treatment.

Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee

Project Stargate will see companies like Oracle, SoftBank, MGX, and OpenAI commit an initial $100 billion to build data centers in the U.S.

What Hartford Funds and Ned Davis Research found was that income stocks more than doubled the average annual return of non-payers -- 9.17% versus 4.27% -- and did so while being less volatile than the benchmark S&P 500. However, high-quality dividend stocks don't grow on trees and require some effort by investors to uncover.

Medical-technology and drug company's 2025 sales outlook is below consensus Johnson & Johnson's stock ... from Dow Jones Newswires and The Wall Street Journal. We sell different types of products ...

The pharmaceutical company’s latest earnings exceeded Wall Street’s expectations as it braces for one of its top-selling medicines to go off patent in the coming weeks.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/100.sbqKNnJW.js

Wall Street has perceived the company to have an almost unbreachable defense against competition with its offerings of high-tech chips. The company’s rapid growth and windfall profit have helped push other technology firms and the Nasdaq Composite Index to record after record,

It wants to crush (forget 'turn back") the clock on diversity and inclusion in America. Fighting bac requires looking back - and getting it right this time.